Aldeyra Therapeutics Inc

NASDAQ: ALDX
$3.20
-$0.05 (-1.5%)
Closing Price on July 3, 2024

ALDX Chart and Intraday Price

ALDX Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 131 HARTWELL AVENUE, SUITE 320, LEXINGTON, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 248.23M USD
Shares Outstanding 58,822,000
Aldeyra Therapeutics Inc is a pioneering biotech firm focused on creating innovative treatments for immune-mediated diseases. Its flagship product, reproxalap, aims to alleviate dry eye diseases and is currently in advanced testing stages. The company is also exploring treatments for COVID-19, asthma, psoriasis, and alcohol intoxication through ADX-629, and tackling rare retinal diseases with ADX-2191. Founded in 2004 and based in Lexington, Massachusetts, Aldeyra is committed to addressing unmet medical needs in inflammation and vision loss.

ALDX Articles

Buffett Grabs More of This Stock, Plus Other Notable Insider Buying
Warren Buffett boosted his stake in this tracking stock again, plus notable insider buying in the past week at biotechs, industrials and more.
Trey Thoelcke
Published:

Insiders Scoop Up Shares of These 5 Stocks for the Second Quarter
A renowned billionaire investor, a French energy giant, and other insiders were scooping up shares of these five stocks as the second quarter began.
Trey Thoelcke
Published: